Not yet recruiting
Exercise Therapy for Women With ANOCA
NCT07733986· NHS Greater Glasgow and Clyde· Source
Contact: Clare Dolan
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· BeOne Medicines· Source
Contact: Study Director
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
NCT07422688· Aarhus University Hospital Skejby· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis
NCT07131969· University of Cambridge· Source
Contact: Mark McPhail
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375· Phase 2· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
NCT06923111· Nova Laboratories Limited· Source
Contact: Hussain Mulla, PhD
Recruiting
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
NCT06985706· Phase 3· Belfast Health and Social Care Trust· Source
Contact: Mary Guiney
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648· Maastricht University· Source
Contact: K. Menon, Dr. (principal investigator)
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953· Phase 3· Institut de Recherches Internationales Servier· Source
Contact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Active, not recruiting
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925· Pfizer· Source
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080· Abbott Medical Devices· Source
Contact: Philip MacCarthy
Active, not recruiting
Avacostar - (PASS)
NCT05897684· Vifor Fresenius Medical Care Renal Pharma· Source
Active, not recruiting
Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation
NCT05564754· Region Skane· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610· Phase 3· Hoffmann-La Roche· Source
Recruiting
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
NCT05967143· Sirtex Medical· Source
Contact: Paul Ross (principal investigator)
Active, not recruiting
Closed-loop for People Living With Cystic Fibrosis Related Diabetes
NCT05562492· University of Cambridge· Source
Recruiting
The SMARTER Cardiomyopathy Study
NCT05750147· Imperial College London· Source
Contact: Study Coordinator
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446· Phase 2· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
RadiothErapy priMIng for CAR-T
NCT04726787· University College, London· Source
Recruiting
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320· Phase 3· Takeda· Source
Contact: Babu Vadamalayan (principal investigator)
Active, not recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· Phase 3· Amgen· Source
Active, not recruiting
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
NCT04788888· Abbott Medical Devices· Source
Active, not recruiting
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
NCT04871919· Alfasigma S.p.A.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
NCT03821610· Phase 2· University of Birmingham· Source
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· Phase 2/3· Celgene· Source
Contact: Reuben BEnjamin, Site 10851
Recruiting
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
NCT03562169· Phase 3· University of Leeds· Source
Contact: Majid Kazmi
Active, not recruiting
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
NCT03049189· Phase 3· ITM Solucin GmbH· Source